Altered cerebral blood flow one month after systemic chemotherapy for breast cancer: A prospective study using pulsed arterial spin labeling MRI perfusion

PLoS ONE

Volumn 9, Issue 5, 2014, Pages

  Nudelman, Kelly N H ^a,b   Wang, Yang ^a   McDonald, Brenna C ^a,c   Conroy, Susan K ^a   Smith, Dori J ^a   West, John D ^a   O'Neill, Darren P ^a   Schneider, Bryan P ^a,c   Saykin, Andrew J ^a,c  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b INDIANA UNIVERSITY SCHOOL OF NURSING   (United States)

^c INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANASTROZOLE; ANTIINFECTIVE AGENT; BEVACIZUMAB; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EXEMESTANE; LETROZOLE; LEUPRORELIN; PACLITAXEL; RALOXIFENE; SUNITINIB; TAMOXIFEN; TRASTUZUMAB; ANTINEOPLASTIC AGENT; SPIN LABELING;

ADULT; ARTICLE; BRAIN BLOOD FLOW; BRAIN PERFUSION; BREAST CANCER; CANCER CHEMOTHERAPY; CEREBROVASCULAR DISEASE; COGNITION; COGNITIVE DEFECT; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DENSITY; FEMALE; GRAY MATTER; HUMAN; MAJOR CLINICAL STUDY; NEUROIMAGING; NEUROPSYCHOLOGICAL TEST; PERFUSION WEIGHTED IMAGING; POSTOPERATIVE PERIOD; PROSPECTIVE STUDY; PULSED ARTERIAL SPIN LABELING MRI PERFUSION; SPIN LABELING; AGED; ARTERY; BRAIN CIRCULATION; BREAST NEOPLASMS; CLINICAL TRIAL; DRUG EFFECTS; MIDDLE AGED; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOLOGY; PATHOPHYSIOLOGY;

ADULT; AGED; ANTINEOPLASTIC AGENTS; ARTERIES; BREAST NEOPLASMS; CEREBROVASCULAR CIRCULATION; COGNITION; FEMALE; GRAY MATTER; HUMANS; MAGNETIC RESONANCE IMAGING; MIDDLE AGED; PROSPECTIVE STUDIES; SPIN LABELS;

EID: 84901236145     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0096713     Document Type: Article

References (49)

1. Howlader N, Noone AM, Krapcho M, Neyman N, Aminou R, et al. (2012) SEER Cancer Statistics Review, 1975-2009 (Vintage 2009 Populations), National Cancer Institute. Available: http://seer.cancer.gov/csr/1975-2009-pops09/.
2. Agrawal K, Onami S, Mortimer JE, Pal SK (2010) Cognitive changes associated with endocrine therapy for breast cancer. Maturitas 67: 209-214.
3. Ahles TA, Saykin AJ, McDonald BC, Furstenberg CT, Cole BF, et al. (2008) Cognitive function in breast cancer patients prior to adjuvant treatment. Breast Cancer Res Treat 110: 143-152. (Pubitemid 351793851)
4. Ahles TA, Saykin AJ, McDonald BC, Li Y, Furstenberg CT, et al. (2010) Longitudinal assessment of cognitive changes associated with adjuvant treatment for breast cancer: impact of age and cognitive reserve. J Clin Oncol 28: 4434-4440.
5. Collins B, Mackenzie J, Stewart A, Bielajew C, Verma S (2009) Cognitive effects of chemotherapy in post-menopausal breast cancer patients 1 year after treatment. Psychooncology 18: 134-143.
6. Falleti MG, Sanfilippo A, Maruff P, Weih L, Phillips KA (2005) The nature and severity of cognitive impairment associated with adjuvant chemotherapy in women with breast cancer: a meta-analysis of the current literature. Brain Cogn 59: 60-70. (Pubitemid 41405841)
7. Fan HG, Houede-Tchen N, Yi QL, Chemerynsky I, Downie FP, et al. (2005) Fatigue, menopausal symptoms, and cognitive function in women after adjuvant chemotherapy for breast cancer: 1- and 2-year follow-up of a prospective controlled study. J Clin Oncol 23: 8025-8032. (Pubitemid 46657404)
8. Holohan KN, Von Ah D, McDonald BC, Saykin AJ (2013) Neuroimaging, cancer, and cognition: state of the knowledge. Semin Oncol Nurs 29: 280-287.
9. Jim HS, Donovan KA, Small BJ, Andrykowski MA, Munster PN, et al. (2009) Cognitive functioning in breast cancer survivors: a controlled comparison. Cancer 115: 1776-1783.
10. Quesnel C, Savard J, Ivers H (2009) Cognitive impairments associated with breast cancer treatments: results from a longitudinal study. Breast Cancer Res Treat 116: 113-123.
11. Wefel JS, Lenzi R, Theriault R, Buzdar AU, Cruickshank S, et al. (2004) 'Chemobrain' in breast carcinoma?: a prologue. Cancer 101: 466-475.
12. Wefel JS, Lenzi R, Theriault RL, Davis RN, Meyers CA (2004) The cognitive sequelae of standard-dose adjuvant chemotherapy in women with breast carcinoma: results of a prospective, randomized, longitudinal trial. Cancer 100: 2292-2299. (Pubitemid 38657875)
13. Bender CM, Sereika SM, Berga SL, Vogel VG, Brufsky AM, et al. (2006) Cognitive impairment associated with adjuvant therapy in breast cancer. Psychooncology 15: 422-430. (Pubitemid 43826855)
14. Schilder CM, Eggens PC, Seynaeve C, Linn SC, Boogerd W, et al. (2009) Neuropsychological functioning in postmenopausal breast cancer patients treated with tamoxifen or exemestane after AC-chemotherapy: cross-sectional findings from the neuropsychological TEAM-side study. Acta Oncol 48: 76-85.
15. Ahles TA, Root JC, Ryan EL (2012) Cancer- and cancer treatment-associated cognitive change: an update on the state of the science. J Clin Oncol 30: 3675-3686.
16. Inagaki M, Yoshikawa E, Matsuoka Y, Sugawara Y, Nakano T, et al. (2007) Smaller regional volumes of brain gray and white matter demonstrated in breast cancer survivors exposed to adjuvant chemotherapy. Cancer 109: 146-156. (Pubitemid 46120202)
17. McDonald BC, Conroy SK, Ahles TA, West JD, Saykin AJ (2010) Gray matter reduction associated with systemic chemotherapy for breast cancer: a prospective MRI study. Breast Cancer Res Treat 123: 819-828.
18. McDonald BC, Conroy SK, Smith DJ, West JD, Saykin AJ (2013) Frontal gray matter reduction after breast cancer chemotherapy and association with executive symptoms: a replication and extension study. Brain Behav Immun 30 Suppl: S117-125.
19. Wang Y, Saykin AJ, Pfeuffer J, Lin C, Mosier KM, et al. (2011) Regional reproducibility of pulsed arterial spin labeling perfusion imaging at 3T. Neuroimage 54: 1188-1195.
20. Detre JA, Wang J, Wang Z, Rao H (2009) Arterial spin-labeled perfusion MRI in basic and clinical neuroscience. Curr Opin Neurol 22: 348-355.
21. McDonald BC, Conroy SK, Ahles TA, West JD, Saykin AJ (2012) Alterations in Brain Activation during Working Memory Processing Associated with Breast Cancer and Treatment: A Prospective Functional MRI Study. J Clin Oncol 30: 2500-2508.
22. Silverman DH, Dy CJ, Castellon SA, Lai J, Pio BS, et al. (2007) Altered frontocortical, cerebellar, and basal ganglia activity in adjuvant-treated breast cancer survivors 5-10 years after chemotherapy. Breast Cancer Res Treat 103: 303-311. (Pubitemid 46944511)
23. Conroy SK, McDonald BC, Ahles TA, West JD, Saykin AJ (2013) Chemotherapy-induced amenorrhea: a prospective study of brain activation changes and neurocognitive correlates. Brain Imaging Behav 7: 491-500.
24. Radloff LS (1977) The CES-D Scale: A self-report depression scale for research in the general population. Appl Psychol Meas 1: 385-401.
25. Spielberger CD (1983) State-Trait Anxiety Inventory. Palo Alto, CA: Consulting Psychologists Press, Inc.
26. Wierenga CE, Clark LR, Dev SI, Shin DD, Jurick SM, et al. (2013) Interaction of age and APOE genotype on cerebral blood flow at rest. J Alzheimers Dis 34: 921-935.
27. Wang DJ, Chen Y, Fernandez-Seara MA, Detre JA (2011) Potentials and challenges for arterial spin labeling in pharmacological magnetic resonance imaging. J Pharmacol Exp Ther 337: 359-366.
28. Maldjian JA, Laurienti PJ, Kraft RA, Burdette JH (2003) An automated method for neuroanatomic and cytoarchitectonic atlas-based interrogation of fMRI data sets. Neuroimage 19: 1233-1239. (Pubitemid 36918259)
29. Conroy SK, McDonald BC, Smith DJ, Moser LR, West JD, et al. (2013) Alterations in brain structure and function in breast cancer survivors: effect of post-chemotherapy interval and relation to oxidative DNA damage. Breast Cancer Res Treat 137: 493-502.
30. Brett M AJ, Valabregue R, Poline JB (2002) Region of interest analysis using an SPM toolbox. 8th International Conference on Functional Mapping of the Human Brain. Sendai, Japan: NeuroImage.
31. Cimprich B, Reuter-Lorenz P, Nelson J, Clark PM, Therrien B, et al. (2010) Prechemotherapy alterations in brain function in women with breast cancer. J Clin Exp Neuropsychol 32: 324-331.
32. Scherling C, Collins B, Mackenzie J, Bielajew C, Smith A (2012) Prechemotherapy differences in response inhibition in breast cancer patients compared to controls: a functional magnetic resonance imaging study. J Clin Exp Neuropsychol 34: 543-560.
33. Scherling C, Collins B, Mackenzie J, Bielajew C, Smith A (2011) Prechemotherapy differences in visuospatial working memory in breast cancer patients compared to controls: an FMRI study. Front Hum Neurosci 5: 122.
34. Ahles TA, Saykin AJ (2007) Candidate mechanisms for chemotherapy-induced cognitive changes. Nat Rev Cancer 7: 192-201.
35. Saykin AJ, Ahles TA, McDonald BC (2003) Mechanisms of chemotherapy-induced cognitive disorders: neuropsychological, pathophysiological, and neuroimaging perspectives. Semin Clin Neuropsychiatry 8: 201-216. (Pubitemid 37474731)
36. Walker CH, Drew BA, Antoon JW, Kalueff AV, Beckman BS (2012) Neurocognitive effects of chemotherapy and endocrine therapies in the treatment of breast cancer: recent perspectives. Cancer Invest 30: 135-148.
37. Dietrich J, Han R, Yang Y, Mayer-Proschel M, Noble M (2006) CNS progenitor cells and oligodendrocytes are targets of chemotherapeutic agents in vitro and in vivo. J Biol 5: 22.
38. Gangloff A, Hsueh WA, Kesner AL, Kiesewetter DO, Pio BS, et al. (2005) Estimation of paclitaxel biodistribution and uptake in human-derived xenografts in vivo with (18)F-fluoropaclitaxel. J Nucl Med 46: 1866-1871. (Pubitemid 46196649)
39. Ginos JZ, Cooper AJ, Dhawan V, Lai JC, Strother SC, et al. (1987) [13N]cisplatin PET to assess pharmacokinetics of intra-arterial versus intravenous chemotherapy for malignant brain tumors. J Nucl Med 28: 1844-1852. (Pubitemid 18017095)
40. Troy L, McFarland K, Littman-Power S, Kelly BJ, Walpole ET, et al. (2000) Cisplatin-based therapy: a neurological and neuropsychological review. Psychooncology 9: 29-39. (Pubitemid 30110388)
41. Verstappen CC, Heimans JJ, Hoekman K, Postma TJ (2003) Neurotoxic complications of chemotherapy in patients with cancer: clinical signs and optimal management. Drugs 63: 1549-1563. (Pubitemid 36976138)
42. Bar-Joseph H, Ben-Aharon I, Tzabari M, Tsarfaty G, Stemmer SM, et al. (2011) In vivo bioimaging as a novel strategy to detect doxorubicin-induced damage to gonadal blood vessels. PLoS One 6:e23492.
43. Vacca A, Ribatti D, Iurlaro M, Merchionne F, Nico B, et al. (2002) Docetaxel versus paclitaxel for antiangiogenesis. J Hematother Stem Cell Res 11: 103-118. (Pubitemid 34163774)
44. Wang J, Lou P, Lesniewski R, Henkin J (2003) Paclitaxel at ultra low concentrations inhibits angiogenesis without affecting cellular microtubule assembly. Anticancer Drugs 14: 13-19. (Pubitemid 36177350)
45. Pachnicki JP, Czeczko NG, Tuon F, Cavalcanti TS, Malafaia AB, et al. (2012) Immunohistochemical evaluation of estrogen and progesterone receptors of pre and post-neoadjuvant chemotherapy for breast cancer. Rev Col Bras Cir 39: 86-92.
46. Dashjamts T, Yoshiura T, Hiwatashi A, Yamashita K, Monji A, et al. (2011) Simultaneous arterial spin labeling cerebral blood flow and morphological assessments for detection of Alzheimer's disease. Acad Radiol 18: 1492-1499.
47. Ahles TA, Saykin AJ, Furstenberg CT, Cole B, Mott LA, et al. (2002) Neuropsychologic impact of standard-dose systemic chemotherapy in long-term survivors of breast cancer and lymphoma. J Clin Oncol 20: 485c493.
48. de Ruiter MB, Reneman L, Boogerd W, Veltman DJ, van Dam FS, et al. (2011) Cerebral hyporesponsiveness and cognitive impairment 10 years after chemotherapy for breast cancer. Hum Brain Mapp 32: 1206-1219.
49. Barona A, Reynolds C, Chastain R (1984) A demographically based index of pre-morbid intelligence for the WAIS-R. J Consult Clin Psych 52: 885-887.